Claims

1. Use of a combination in the manufacture of a medicament for treating migraine in a human migraine patient with a history of inadequate response to prior migraine treatments, wherein the medicament is to be orally administered to the migraine patient, and wherein the medicament comprises a combination of meloxicam complexed with sulfobutyl ether β-cyclodextrin (SBEβCD), a bicarbonate, and a rizatriptan.

2. The use of claim 1, wherein the human migraine patient experiences relief of the migraine pain as a result of the oral administration of the medicament to the migraine patient.

3. The use of claim 1 or 2, wherein the human migraine patient is free of migraine pain two hours after the medicament has been orally administered to the human migraine patient.

4. The use of claim 1, 2, or 3, wherein the migraine patient has nausea, photophobia , or phonophobia, or a combination thereof, and wherein the migraine patient experiences a reduction in nausea, photophobia, or phonophobia as a result of the oral administration of the medicament to the migraine patient.

5. The use of claim 4, wherein the human migraine patient is free of nausea, photophobia, or phonophobia two hours after the medicament has been orally administered to the human migraine patient.

6. The use of claim 1, 2, 3, 4, or 5, ~~or 6,~~ wherein the combination contains ~~about~~ 5 mg to ~~about~~ 50 mg of the meloxicam.

7. The use of claim 1, 2, 3, 4, 5, or 6, ~~7, or 8,~~ wherein the medicament is a solid oral medicament ~~comprising a combination of: 1) a complex of meloxicam with a sulfobutyl ether β-cyclodextrin (SBEβCD), 2) a bicarbonate, and 3) the rizatriptan~~, wherein the medicament has a shorter T_{max} of meloxicam in the human being than a reference medicament that: 1) contains the same amount of meloxicam, 2) does not contain an SBEβCD, 3) does not contain a rizatriptan, and 4) does not contain a bicarbonate.

8. The use of claim 1, 2, 3, 4, 5, 6, or 7, wherein ~~about~~ 1 mg to ~~about~~ 50 mg of the rizatriptan is present in the oral medicament based upon the weight of the rizatriptan in the free base form.

9. The -use of claim 8, wherein the rizatriptan is present in a salt form in an amount that is a molar equivalent of ~~about~~ 10 mg of the rizatriptan in the free base form.

10. The -use of claim 8 or 9, wherein the rizatriptan is present as rizatriptan benzoate.

11. The use of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, wherein the oral -medicament contains ~~about~~ 10 mg to ~~about~~ 30 mg of the meloxicam.

12. The –use of claim 11, wherein the oral medicament contains ~~about~~ 20 mg of the meloxicam.

13. The -use of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12, wherein the SBEβCD has ~~about~~ 6 to ~~about~~ 7 sulfobutyl ether groups for each molecule of β-cyclodextrin.

14. The use of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13, wherein the oral dosage form contains ~~about~~ 50 mg to ~~about~~ 200 mg of the SBEβCD.

15. The use of claim 14, wherein the oral medicament contains ~~about~~ 100 mg of the SBEβCD.

16. The –use of claim 1, 2, 3, 4, 5, 6, 7, 8, ~~9,~~ 10, ~~11, 12,~~ 13, 14, or 15, wherein the oral medicament contains ~~about~~ 10 mg to ~~about~~ 40 mg of the meloxicam, and ~~about~~ 5 mg to ~~about~~ 50 mg of the rizatriptan.

17. The –use of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16, wherein the bicarbonate comprises 500 mg of sodium bicarbonate.

18. The -use of claim 17, wherein the oral -medicament has been shown to have a median T_{max} of meloxicam that is less than ~~about~~ 2 hours in fasted human subjects.

19. The -use of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18, wherein the oral -medicament has been shown to have faster time to therapeutic plasma concentration in the human being as compared to the reference medicament.

20. The use of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, or 19, wherein the combination contains 400 mg to 600 mg of the bicarbonate.